Literature DB >> 22759796

The dual role of pharmacogenetics in HIV treatment: mutations and polymorphisms regulating antiretroviral drug resistance and disposition.

Veronique Michaud1, Tamara Bar-Magen, Jacques Turgeon, David Flockhart, Zeruesenay Desta, Mark A Wainberg.   

Abstract

Significant intra- and interindividual variability has been observed in response to use of pharmacological agents in treatment of HIV infection. Treatment of HIV infection is limited by high rates of adverse drug reactions and development of resistance in a significant proportion of patients as a result of suboptimal drug concentrations. The efficacy of antiretroviral therapy is challenged by the emergence of resistant HIV-1 mutants with reduced susceptibility to antiretroviral drugs. Moreover, pharmacotherapy of patients infected with HIV is challenging because a great number of comorbidities increase polypharmacy and the risk for drug-drug interactions. Drug-metabolizing enzymes and drug transporters regulate drug access to the systemic circulation, target cells, and sanctuary sites. These factors, which determine drug exposure, along with the emergence of mutations conferring resistance to HIV medications, could explain variability in efficacy and adverse drug reactions associated with antiretroviral drugs. In this review, the major factors affecting the disposition of antiretroviral drugs, including key drug-metabolizing enzymes and membrane drug transporters, are outlined. Genetic polymorphisms affecting the activity and/or the expression of cytochromes P450 or UGT isozymes and membrane drug transport proteins are highlighted and include such examples as the association of neurotoxicity with efavirenz, nephrotoxicity with tenofovir, hepatotoxicity with nevirapine, and hyperbilirubinemia with indinavir and atazanavir. Mechanisms of drug resistance conferred by specific viral mutations are also reviewed, with particular attention to replicative viral fitness and transmitted HIV drug resistance with the objectives of providing a better understanding of mechanisms involved in HIV drug resistance and helping health care providers to better manage interpatient variability in drug efficacy and toxicity.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22759796     DOI: 10.1124/pr.111.005553

Source DB:  PubMed          Journal:  Pharmacol Rev        ISSN: 0031-6997            Impact factor:   25.468


  32 in total

Review 1.  Drug transporters in tissues and cells relevant to sexual transmission of HIV: Implications for drug delivery.

Authors:  Minlu Hu; Sravan Kumar Patel; Tian Zhou; Lisa C Rohan
Journal:  J Control Release       Date:  2015-08-13       Impact factor: 9.776

2.  Synthesis and structure-activity analysis of diphenylpyrazolodiazene inhibitors of the HIV-1 Nef virulence factor.

Authors:  Prema C Iyer; Jielu Zhao; Lori A Emert-Sedlak; Kerry K Moore; Thomas E Smithgall; Billy W Day
Journal:  Bioorg Med Chem Lett       Date:  2014-02-26       Impact factor: 2.823

Review 3.  Evolutionary consequences of drug resistance: shared principles across diverse targets and organisms.

Authors:  Diarmaid Hughes; Dan I Andersson
Journal:  Nat Rev Genet       Date:  2015-07-07       Impact factor: 53.242

4.  Drug metabolism and transport gene polymorphisms and efavirenz adverse effects in Brazilian HIV-positive individuals.

Authors:  Tailah Bernardo de Almeida; Marcelo Costa Velho Mendes de Azevedo; Jorge Francisco da Cunha Pinto; Fernando Rafael de Almeida Ferry; Guilherme Almeida Rosa da Silva; Izana Junqueira de Castro; Paxton Baker; Amilcar Tanuri; David W Haas; Cynthia C Cardoso
Journal:  J Antimicrob Chemother       Date:  2018-09-01       Impact factor: 5.790

5.  Genomewide association study of tenofovir pharmacokinetics and creatinine clearance in AIDS Clinical Trials Group protocol A5202.

Authors:  Valentine Wanga; Charles Venuto; Gene D Morse; Edward P Acosta; Eric S Daar; David W Haas; Chun Li; Bryan E Shepherd
Journal:  Pharmacogenet Genomics       Date:  2015-09       Impact factor: 2.089

Review 6.  PharmGKB summary: Efavirenz pathway, pharmacokinetics.

Authors:  Ellen M McDonagh; Johnathan L Lau; Maria L Alvarellos; Russ B Altman; Teri E Klein
Journal:  Pharmacogenet Genomics       Date:  2015-07       Impact factor: 2.089

Review 7.  Pharmacology of Antiretrovirals in the Female Genital Tract for HIV Prevention.

Authors:  Melanie R Nicol; Joseph A Corbino; Mackenzie L Cottrell
Journal:  J Clin Pharmacol       Date:  2018-06-14       Impact factor: 3.126

Review 8.  Neurotoxicity in the Post-HAART Era: Caution for the Antiretroviral Therapeutics.

Authors:  Ankit Shah; Mohitkumar R Gangwani; Nitish S Chaudhari; Alexy Glazyrin; Hari K Bhat; Anil Kumar
Journal:  Neurotox Res       Date:  2016-06-30       Impact factor: 3.911

9.  Pharmacokinetic Changes during Pregnancy According to Genetic Variants: a Prospective Study in HIV-Infected Patients Receiving Atazanavir-Ritonavir.

Authors:  Emanuele Focà; Andrea Calcagno; Andrea Bonito; Jessica Cusato; Elisabetta Domenighini; Antonio D'Avolio; Eugenia Quiros Roldan; Laura Trentini; Filippo Castelnuovo; Giovanni Di Perri; Francesco Castelli; Stefano Bonora
Journal:  Antimicrob Agents Chemother       Date:  2018-06-26       Impact factor: 5.191

10.  Effects of Antiviral Drugs on Organic Anion Transport in Human Placental BeWo Cells.

Authors:  Tomohiro Nabekura; Tatsuya Kawasaki; Yuki Kamiya; Yuichi Uwai
Journal:  Antimicrob Agents Chemother       Date:  2015-09-28       Impact factor: 5.191

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.